• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Emergent BioSolutions

    Adare Pharma Solutions

    Aphena Pharma Solutions

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Syngene

    Cytovance Biologics

    Adare Pharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Solid Dosage Outsourcing Trends

    The market continues to evolve as blockbusters are replaced by more targeted treatments that have unique requirements.

    Related CONTENT
    • Phlow Corp. and USP Form Alliance
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    • Solid Dose Market Trends
    • Manufacturing Equipment Trends
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    Tim Wright, Editor03.09.16
    The oral solid dosage form is a cornerstone of the contract manufacturing industry. The market remains ripe with opportunities for contract manufacturers that are able to differentiate through niche technologies, capabilities and other value-add propositions. The service providers Contract Pharma spoke to about the state of the market all cited an upswing in outsourcing activity.

    A new report published by Transparency Market Research titled “Oral Solid Dosage Forms and Pharma Excipients Market,” said the global oral solid dosage forms market was worth $571 million in 2011 and is projected to climb to $870 million by the end of 2018, growing on average of 6.3% per year.

    “There is a lot of capacity in solid dose manufacturing across the globe, so just having capacity is not necessarily a differentiator,” said Kaspar van den Dries, senior director and principal scientist of solid dose development, Patheon. “Pharmaceutical companies are looking for expanded services such as integrated API, drug product services and flexible manufacturing capacity to be able to handle the intrinsic variable demands, especially at the time of product launch.”

    At the same time there is a dwindling number of independent companies now left in the U.S. as a result of the need for scale in technology. “More European companies with less advanced facilities are in need of U.S. real estate, but cannot afford it,” said Derek Hennecke, president and CEO, Xcelience, part of Capsugel Dosage Form Solutions. “Asia is becoming less important for U.S.- and European-based companies, which have been hit hard by quality problems in India.”

    The strong market demand for oral technologies is also witnessing an increased focus on robust formulation development due to fewer blockbusters, patent cliffs and constrained R&D budgets.

    “The market for contract manufacturing and development services is strong as companies look to optimize their networks,” said Aileen Ruff, vice president, strategy and marketing, advanced delivery technologies, Catalent Pharma Solutions. “In the years ahead, this network optimization trend will likely drive increased consolidation across both pharma companies and suppliers. We will also see significant focus on oral delivery of large molecules as science and technology rapidly evolve to achieve this ‘holy grail’ of oral drug delivery.”

    Ms. Ruff also pointed out an increased demand for generics as marketed products come off patent, particularly in Europe where price pressures are significant. “In the U.S., the specialty pharmaceutical segment remains strong, but from companies of all sizes there is continued demand for modified release and other complex formulations across both branded prescription and consumer health products, for example, to address compliance issues and minimize side effects,” she said.

    Mr. Hennecke sees an emphasis on smaller scale products such as orphan drugs and pediatric applications. “We remain optimistic about the market as a whole based on the number of Phase 3 projects coming to market, and the amount of spending money raised by biotechs last year,” he said. “We do not see any pending changes in government policy to curtail R&D. The orphan drugs laws and incentives remain in place and are not likely to be revoked over the next two years.”

    While the CDMO market is growing at a healthy rate, and this growth is expected to continue, one complexity involved is the fact that transferring, changing or improving existing manufacturing processes is still an under-evolved aspect of pharmaceutical manufacturing, according to Mr. van den Dries. “Global supply chains of pharmaceutical products are complex and regulations sometimes restrict the ability for continuous improvement or increasing flexibility in the supply chain,” he said. “Of course, there is also increased pressure on healthcare budgets, meaning that efficiency has to increase and costs have to go down to remain competitive in the business.

    “Another aspect of today’s solid dose manufacturing is increased attention to the science and knowledge of these processes,” he continued. “Where in the past some processes were developed by art rather than science, significant efforts are currently being made through the Quality by Design (QbD) paradigm to improve the robustness of processes, and thereby the reliability.”

    Living in Niche Times
    The age of the blockbuster is widely acknowledged to be over. Innovative company strategies now include operating in more niche fields and developing more complex formulations that are difficult to replicate by generic players.

    As a result, more specialized niche plants are being built, which fulfill the need for specialized enabling technology as well as enhanced speed and agility, according to Mr. Hennecke. “They are perfect for growing patient-centric dosage forms such as pediatric formulations, orphan drugs and 505(b)(2) applications,” he said. “Specialized partnerships can be formed for product development and manufacturing of such small scale/high value products.

    “We continue to focus on such specialty applications, with an array of bioavailability enhancing technologies,” he added. “Indeed, the majority of products in the pharmaceutical pipeline are in the specialty and orphan drug designations, oftentimes requiring enabling technologies and specialized processing. These applications also typically need small and flexible scale manufacturing and high containment to efficiently and safely produce these products. We are operating in a pretty open field right now, as most CMOs were built for the large volumes of yesterday’s blockbuster.”

    Ms. Ruff concurred, saying that with fewer blockbusters in the pipeline, companies are taking a more targeted approach to treat narrower disease states or patient populations, or looking to improve upon existing marketed products with next generation treatments that offer more optimal results. “More and more compounds in the pipeline have more complex delivery profiles, including precise release requirements, combinations of different APIs, and delivery needs in specific parts of the body for increased efficacy,” she said.

    Mr. van den Dries said, “As the blockbuster drug model continues to evolve into a more personalized medicine and orphan indication, which means an increase in low-volume products and more specialized dosage forms, the pharmaceutical industry is just starting to react to these trends and understanding what it means for existing business models and manufacturing technologies.”

    Opportunities Abound
    There are a number of opportunities for growth, both from a technology standpoint as well as an integrated model for supporting client projects. New technologies are in high demand for overcoming bioavailability challenges.

    “Bioavailability issues are common in today’s market, with an estimated 70% of drugs in the pipeline classified as poorly soluble,” said Ms. Ruff. “One challenge in optimizing the solubility of a molecule is that it often requires a multi-faceted approach to optimize the API, optimize the formulation, select and optimize the processing technology, and develop the desired marketed product form, such as a tablet or capsule.”

    She said another challenge is in delivering drugs that are broken down by low pH in the stomach. “Tailored enteric coating or resistant capsules containing mini-tablets or pellets are a potential solution for local gut delivery and improved systemic availability. Then there are also the challenges of controlling release, tailoring delivery, preventing abuse and ensuring patient adherence. 

    “There is also opportunity for innovative oral solid products that offer flexibility in timing of medication release, reduce side effects, optimize dosing schedules, drive patient adherence, or address the unique needs of certain patient segments such as pediatrics or the elderly, or individuals that may have trouble swallowing. These types of advanced drug delivery forms offer distinct marketing and brand advantages for customers while adding clear value for patients.”

    In addition to technology for improved bioavailability, pediatric formulations are another area for growth, according to Mr. Henneke. “We are seeing increased application of our multi-particulate technologies and requirements for effective taste-masking,” he said. “Also, enabling viable alternatives to IV delivery remains an open opportunity. We see growing demand for new oral delivery approaches targeting the lungs.”

    The CDMO market is still growing as more and more pharma and biotech companies are divesting chemistry and manufacturing controls (CMC) development and commercial manufacturing to focus on their core strengths of researching new molecules for treatment of diseases, according to Mr. van den Dries. “In addition, so-called virtual companies are also increasing in number, but have no internal manufacturing capacity and rely on contractors to assist them in bringing their inventions to reality,” he said. “One key challenge is that the CDMO market is highly fragmented with a lot of niche players in the field. This makes it complicated for pharma companies to identify the best solution providers for them, as the number of CDMOs and offerings they must screen as part of their due diligence in finding the best partner is significant.”

    Customer Expectations
    Pharmaceutical pipelines today require more flexibility in manufacturing than ever before. According to Ms. Ruff, there is an increasing demand for customized technical and business solutions, as blockbusters are replaced by more targeted treatments that have unique requirements. “We believe that the need for flexible solutions to bring specific products to market faster as part of a flexible manufacturing network strategy is key,” she said. “This entails providing customers with deep capabilities in key areas including customized solutions for complex products, potent drugs, fast and reliable product launches and meeting the need for fast and efficient technology transfers, unique solutions such as customized manufacturing suites and the capacity to support the demand for tailored manufacturing solutions.”

    Mr. Hennecke said he is seeing more demand for drug design work versus “rescue missions,” as clients realize the need to involve their development partners at the earliest stages in order to better ensure success. “Historically, many clients engaged us to develop products based on their or other partners’ design, and oftentimes we would redefine the problem statement and redesign the formulation,” he said. “Speed to clinic remains a key concern and does not differ from the virtual client to big pharma—clients expect a tailored approach regardless of size, a high degree of collaboration, and the ability to take the product to clinic and commercial scale.”

    For Mr. van den Dries, Patheon’s clients are evolving from treating the company as a tactical vendor to viewing it as a strategic partner. “Where in the past requests were largely about the capacity to manufacture clinical and/or commercial supply, the dialogue is now more about providing solutions in development and supply chain, and the desire to reduce total cost of ownership of these outsourced projects,” he said.

    Solid (Dosage) Investing
    Service providers continue to respond to client-specific needs and the general market trends with continued expansion of service offerings, capabilities and capacity.

    In April 2015, Catalent opened a $52 million dollar expansion to its Winchester, KY, facility, doubling its footprint to 180,000 square feet. The investment included a new fluid bed, large analytical lab, and ability to provide integrated specialty packaging services. The expanded space provides the flexibility to handle large volumes, and the open footprint and large interstitial space also offers flexibility in designing custom or dedicated suites based on program requirements. In December 2015, Pfizer selected Catalent’s Winchester facility to formulate and manufacture its leading over-the-counter heartburn treatment, Nexium 24HR.

    Across the oral solids business as a whole, Catalent has established end-to-end hot melt extrusion (HME) delivery platforms in both the U.S. and Europe. This HME offering, along with softgel and micronization capabilities, provides a suite of solutions to address bioavailability challenges. The Zydis orally dissolvable tablet (ODT) technology offers adherence and swallowability advantages, with a formulation that dissolves in less than three seconds. Catalent continues to invest in its Zydis platform to achieve higher drug loading and optimal taste masking.

    Investment in 2015 at Catalent’s headquarters in Somerset, NJ, created a manufacturing Center of Excellence for potent handling across the company’s portfolio of oral solid manufacturing solutions, which included expansion in its high-shear and wet granulation processing, solvent-based capability, extrusion/spheronization, fluid-bed processing, Wurster coating, and compression and encapsulation platforms.

    Catalent also recently announced it had created a dedicated Science and Technology organization within the company that will bring together internal experts across multiple technologies and disciplines to enhance collaborative scientific development between Catalent, its customers and partners, and accelerate the development of drug products through the use of advanced formulation and drug delivery technologies.

    Catalent is also developing a novel dry coating process using acoustic mixing to taste-mask API molecules. These APIs, when formulated into tablets, provide effective taste masking while maintaining the desired dissolution release characteristics.

    For Capsugel, the big news is that it acquired both Xcelience and Powdersize on Jan. 4 with both being integrated into the Capsugel Dosage Form Solutions business unit. Capsugel can now fully integrate the design, development and manufacture of innovative dosage forms across its range of solid dosage forms while addressing key formulation challenges, including low solubility and controlling or targeting release more effectively.

    The acquisition of Powdersize gave Capsugel micronization capabilities, allowing it to engage clients at the earliest stages of development. Capsugel also wanted to offer solid dispersion technology, specifically spray drying, to its clients facing solubility challenges. The company said it would have been relatively easy to add a small-scale spray dryer, but quite a challenge to develop the operating expertise or provide phase-appropriate scale throughout the product development process. 

    As the integration gains momentum, Capsugel is adding capacity and capabilities across technologies and product development sites. Capacity and product development teams have been expanded at sites to support liquid fill hard capsule and softgel technologies. A spray drying commercial manufacturing facility was added at Bend Research, also part of Capsugel Dosage Form Solutions. Powdersize just added a new Netzsche nano-mill to complement Capsugel’s particle engineering offering. In addition, Capsugel has expanded its product development teams and capabilities in Tampa, FL, where Xcelience is based.

    Capsugel has a number of oral dosage enhancing technologies. Last November, it launched enTRinsic drug delivery technology, the industry’s first fully enteric dosage form without the need for functional coating, according to the company, and is seeing a lot of interest for enabling oral delivery of sensitive molecules such as proteins, nucleotides and live biotherapeutic products.

    Patheon is making significant investments to expand its solid dose development and manufacturing capabilities. An example of this investment is visible in its solid dose site location at Bourgoin-Jaillieu in France, where the pharmaceutical development services (PDS) business has invested in a small scale GEA high shear/fluid bed granulation line with an operating range between 4-20 kg and a Gerteis roller compactor. Since the industry is seeing an increasing trend in the demand for handling high potent APIs (HPAPI), this additional equipment has containment at source and the ability to develop processes for HPAPIs. The commercial unit is investing in expanded high potency capabilities, with a large-scale pan coater (~350 kg) and dedicated dispensing isolator. Also, pharmaceutical packaging investments are being made in new lines able to handle high-potent products, including serialization.

    In addition to the capacity expansion in its high-potency offerings, one other unique investment is happening at the Greenville, NC, site where Patheon is currently installing a continuous manufacturing line that is able to produce solid dose products by dry mixing, wet granulation or dry granulation in a continuous process.

    Another key acquisition was that of Agere, based in Bend, OR, which specializes in spray drying and solubilization technologies. With its existing footprint in solubilization technologies in Milton Park, U.K. and through softgel sites in High Point, NC, and Tilburg, The Netherlands, Patheon now has a comprehensive offering of solibilization enhancement solutions. This not only focuses on screening and production of clinical supplies, but also includes the option to screen technologies in silico through molecular modeling capabilities and technology selection tools. According to the company, since more than 70% of molecules exhibit poor solubility that could limit bioavailability, these services are an important aspect in support of current pharmaceutical development programs. 


    Tim Wright is the editor of Contract Pharma. He can be reached at twright@rodmanmedia.com.
    Related Searches
    • orphan
    • apis
    • prescription
    • Formulation Development
    Suggested For You
    Phlow Corp. and USP Form Alliance Phlow Corp. and USP Form Alliance
    Ashfield Engage, Popit Form Digital Monitoring Collaboration Ashfield Engage, Popit Form Digital Monitoring Collaboration
    Solid Dose Market Trends Solid Dose Market Trends
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    ACG Launches ACG Laboratories ACG Launches ACG Laboratories
    Glatt and Aprecia Enter 3D-Printing Collaboration Glatt and Aprecia Enter 3D-Printing Collaboration
    CDMO Recro Strengthens Leadership Team CDMO Recro Strengthens Leadership Team
    Aphena’s $21M Cookeville Expansion Nears Completion Aphena’s $21M Cookeville Expansion Nears Completion
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Improving Product Profitability Improving Product Profitability
    Pharmaceutical and Biotherapeutic Development and Testing Pharmaceutical and Biotherapeutic Development and Testing
    The Importance of Food Studies in Pharmaceutical Development The Importance of Food Studies in Pharmaceutical Development
    Thermo Fisher Scientific Further Expands Global Footprint Thermo Fisher Scientific Further Expands Global Footprint
    Tjoapack Invests $12.1M in Packaging & Supply Chain Facility Tjoapack Invests $12.1M in Packaging & Supply Chain Facility

    Related Features

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • Formulation Development
      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      A strong trend in drug substance and drug product biomanufacturing, as is for formulation, is that of increasing therapeutic complexity.
      Latika Bhonsle-Deeng, Rentschler Biopharma SE, and Konstantin Petropoulos, LEUKOCARE AG 10.14.20

    • Drug Delivery
      Wet Wipes Increased Prevalence in Drug Development

      Wet Wipes Increased Prevalence in Drug Development

      A number of factors including patient preference are driving the growth of wet wipes in pharma.
      John Waddell, Business Development Director – Pharma, PDI Contract Manufacturing 10.14.20

    • Drug Delivery
      Not Your Father’s Oral Thin Film

      Not Your Father’s Oral Thin Film

      A look at how oral film drug delivery is evolving.
      Rodolphe Obeid, Vice President of Operations, IntelGenx 06.04.20


    • Drug Delivery | Regulatory Affairs
      Regulatory Overhaul for Medical Devices

      Regulatory Overhaul for Medical Devices

      Implications for the pharmaceutical industry.
      Elizma Parry, Director, Global Clinical Practice, Maetrics 06.04.20

    • Drug Delivery
      CEO Spotlight: Will Downie

      CEO Spotlight: Will Downie

      Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO
      Tim Wright, Editor, Contract Pharma 04.01.20

    • Chemistry
      Greener by Design

      Greener by Design

      How new approaches to green chemistry are driving sustainable processes.
      Kenneth Ball, Commercial Operations Lead, Pfizer CentreOne 03.04.20


    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Delivery
      Nasal Drug Delivery

      Nasal Drug Delivery

      A look at best practices for testing nasal drug delivery devices
      Maria Smith, senior manager & Charles Shaw, scientific advisor, Renaissance Lakewood LLC 01.25.19

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login